A Trial of SHR-1703 in Healthy Adults

NCT ID: NCT04480762

Last Updated: 2022-11-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-04
• Study Completion Date: 2021-09-21

Brief Summary

SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the first study in Healthy subjects. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose SHR-1703 administered subcutaneously in Chinese healthy subjects.

Detailed Description

This study will be conducted at 1 study center in China. Approximately 42 healthy Chinese male and female subjects, aged 18 to 55 inclusive, will be randomized to receive a single SC administration of SHR-1703: Treatment 1, Treatment 2, Treatment 3, Treatment 4 and Treatment 5. Each subject will participate in only 1 treatment group. The total length of the study for each subject is up to 190 days (28 days of screening and 155+/- 7 days of further study visits).

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

SHR-1703-Subcutaneous administration of Dose 1

A single subcutaneous injection of SHR-1703 (Dose 1) or Placebo

Group Type: EXPERIMENTAL

SHR-1703

Intervention Type: DRUG

SHR-1703

Placebo

Intervention Type: DRUG

Placebo of the SHR-1703

SHR-1703-Subcutaneous administration of Dose 2

A single subcutaneous injection of SHR-1703 (Dose 2) or Placebo

Group Type: EXPERIMENTAL

SHR-1703

Intervention Type: DRUG

SHR-1703

Placebo

Intervention Type: DRUG

Placebo of the SHR-1703

SHR-1703-Subcutaneous administration of Dose 3

A single subcutaneous injection of SHR-1703 (Dose 3) or Placebo

Group Type: EXPERIMENTAL

SHR-1703

Intervention Type: DRUG

SHR-1703

Placebo

Intervention Type: DRUG

Placebo of the SHR-1703

SHR-1703-Subcutaneous administration of Dose 4

A single subcutaneous injection of SHR-1703 (Dose 4) or Placebo

Group Type: EXPERIMENTAL

SHR-1703

Intervention Type: DRUG

SHR-1703

Placebo

Intervention Type: DRUG

Placebo of the SHR-1703

SHR-1703-Subcutaneous administration of Dose 5

A single subcutaneous injection of SHR-1703 (Dose 5) or Placebo

Group Type: EXPERIMENTAL

SHR-1703

Intervention Type: DRUG

SHR-1703

Placebo

Intervention Type: DRUG

Placebo of the SHR-1703

Interventions

SHR-1703

SHR-1703

Intervention Type: DRUG

Placebo

Placebo of the SHR-1703

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
• Able to read, comprehend and write at a sufficient level to complete study materials.
• Aged 18 to 55 years (inclusive).
• Body weight equal or more than 45.0 kg and BMI within the range between 19 and 24kg/m2 (inclusive).
• AST, ALT, alkaline phosphatase and bilirubin equal or less than ULN.
• Healthy Chinese as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the Jiangsu HengRui Medicine Co Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
• Subjects must commit to consistent and correct use of an acceptable method of birth control from the start of trial to the next month after the last visit.
• A negative pre-study drug/alcohol screen.

Exclusion Criteria

• Allergy/intolerance to the SHR-1703 and/or excipients in the formulation, or any other Biologics
• Positive Hepatitis B surface antigen or positive Hepatitis C antibody or human immunodeficiency virus - HIV antibody or Syphilis serological test at screening
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to screening in the current study: 3 months, 5 half-lives or fellow-up period of the investigational product (whichever is longer).
• Use of any medicines, including prescription or Over-the-Counter drugs (including herbal and dietary supplements, not including regular vitamins and paracetamol which be used occasionally in the recommended dose) within 1 month or 5 half-lives (whichever is longer) prior to the administration.
• Subjects who have received immune inhibitors within 6 months prior to screening
• Subjects who have had severe trauma or surgery within 6 months prior to screening, or who plan to undergo surgery during the trial.
• Blood donation history within 1 month prior to screening ,or severe blood loss(total blood volume≥400 ml)，or blood transfusion within 2 months
• Subjects who are inoculated live (attenuated) vaccine within 1 month prior to screening or during the trial.
• Subject who is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.
• At the discretion of the investigator, a subject will not be eligible for this study if he/she is in the following cases: the subject is not able to complete the study, or present a significant risk to the subject, or present other factors(e.g. infirmity. etc.) that may prevent the enrolment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Countries

China

References

Yang L, Fang Y, Luo Y, Fu M, Shen K, Luo Z. Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study. Expert Opin Investig Drugs. 2024 Jul;33(7):741-752. doi: 10.1080/13543784.2024.2361065. Epub 2024 Jun 3.

Reference Type: DERIVED

PMID: 38805242 (View on PubMed)

Other Identifiers

SHR-1703-101

Identifier Type: -

Identifier Source: org_study_id